Clinical Trials Browser

Melanoma

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Phase EARLY_PHASE1 Recruiting

50 enrolled

Dermatologic

Melanoma

NCT06305962 2026-02-19

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Phase EARLY_PHASE1 Recruiting

30 enrolled

BreastDermatologicGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

A Study of GC101 TIL in Advanced Melanoma (10hospital)

Mel 70

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

CITY

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Zr89 + PET Companion Trial

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis